[CLSTR]
< Back to situations

[ORGANIZATION]

Bristol Myers Squibb

Featured in 19 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [CN] [US]

China biopharmaceutical industry growth

2 clusters · 13 sources · last updated

Latest: China's biopharma rise reshapes global innovation and dealmaking

China is expanding its national health insurance coverage to include more innovative drugs, specifically targeting cancer, chronic, rare, and pediatric conditions. Since 2018, the National Healthcare Security Administrat

[QUIET] [BUSINESS] [CH] [US]

Novartis CAR T cell therapy trial suspensions

2 clusters · 34 sources · last updated

Latest: Novartis shares plunge following dual clinical trial failures

Novartis has halted eight clinical trials involving an experimental CAR T cell therapy following three deaths. The fatalities were linked to immune effector cell-associated hemophagocytic syndrome (IEC-HS), a condition w

[QUIET] [HEALTH] [GB] [US]

Aficamten development for hypertrophic cardiomyopathy

3 clusters · 4 sources · last updated

Latest: New therapies show promise for treating hypertrophic cardiomyopathy

The cardiac myosin inhibitor aficamten (brand name Myqorzo) is expanding its clinical application and regulatory reach for hypertrophic cardiomyopathy (HCM). In England, the Medicines and Healthcare products Regulatory

[QUIET] [HEALTH] [US]

Replimune Tudriqev FDA approval and subsequent legal action

5 clusters · 20 sources · last updated

Latest: Replimune faces lawsuits following TUDRIQEV approval

On 6 August 2026, the FDA granted accelerated approval to Replimune’s oncolytic herpes-virus therapy RP1, marketed as Tudriqev, for use with Bristol Myers Squibb’s Opdivo (nivolumab) in adults with unresectable or metast

[QUIET] [BUSINESS] [US] [CN] [DK]

Global pharmaceutical and biotech industry trends

2 clusters · 3 sources · last updated

Latest: Pharmaceutical industry sees leadership shifts and FDA approvals

The global biotechnology and pharmaceutical sectors have experienced significant activity driven by strategic acquisitions and regulatory milestones. Between January and May 2026, the biotech sector saw 201 mergers and a

[QUIET] [BUSINESS] [US] [DE]

Pharmaceutical manufacturing investment trends

4 clusters · 22 sources · last updated

Latest: Bristol Myers Squibb to invest $2.3B in Houston manufacturing campus

Pharmaceutical companies are making significant investments in manufacturing infrastructure, with a notable focus on expanding capacity within the United States. Eli Lilly and Resilience announced a $750 million partne

Also covered in